Rheumatology Focused Clinical Research

Comprehensive rheumatology trial support across inflammatory arthritis, systemic autoimmune diseases, and connective tissue disorders — with expertise in composite response endpoints and immunogenicity assessments.

Overview

Expertise in Autoimmune & Inflammatory Research

Rheumatic diseases represent a rapidly evolving therapeutic area, driven by advances in biologic therapies, targeted synthetic DMARDs, and emerging cell therapies. Omega CRO provides comprehensive support for rheumatology clinical trials, combining deep therapeutic expertise with specialized laboratory capabilities through the Omega ecosystem.

Our experience encompasses the full spectrum of inflammatory and autoimmune rheumatic diseases. We understand the complexities of composite response criteria (ACR20/50/70, DAS28, PASI), the importance of immunogenicity testing for biologics, and the need for sensitive imaging modalities to detect subclinical disease activity.

Therapeutic Coverage

Rheumatologic Indications

Inflammatory Arthritis

  • Rheumatoid Arthritis (RA)
  • Psoriatic Arthritis (PsA)
  • Axial Spondyloarthritis (AS/non-radiographic axSpA)
  • Juvenile Idiopathic Arthritis (JIA)

Systemic Autoimmune

  • Systemic Lupus Erythematosus (SLE)
  • Systemic Sclerosis (Scleroderma)
  • Sjögren's Syndrome
  • ANCA-Associated Vasculitis

Emerancing Areas

  • Psoriasis (Dermatology crossover)
  • Hidradenitis Suppurativa
  • IgA Nephropathy
  • Osteoarthritis & Bone Health
Specialized Capabilities

Composite Endpoints & Immunogenicity

Composite Response Criteria

  • ACR20/50/70 response criteria for RA
  • DAS28, CDAI, SDAI for disease activity
  • ASAS response criteria for axial SpA
  • SLEDAI, BICLA, SRI-4/6 for lupus
  • Centralized joint counting and imaging review

Immunogenicity & Autoantibody Testing

  • ELISA-based ADA (anti-drug antibody) screening and confirmation
  • Cell-based neutralizing antibody (NAb) assays
  • Rheumatoid factor (RF) and anti-CCP testing
  • ANA, anti-dsDNA, anti-Smith, complement C3/C4
  • ANCA (MPO/PR3) and cryoglobulin testing
Therapeutic Modalities

Biologics, Biosimilars & Targeted Therapies

Extensive experience across all major therapeutic classes used in rheumatology trials.

TNF Inhibitors
IL-6 Inhibitors
IL-17 Inhibitors
IL-23 Inhibitors
JAK Inhibitors
B-cell Depletion
Biosimilars
CAR-T (Emerging)
Omega Research Ecosystem

Application Scenarios in the Omega Ecosystem

How the Omega ecosystem supports rheumatology research\u2014from immunogenicity testing to autoantibody profiling and joint imaging coordination.

HelixLab

Inflammatory & Safety Panels

CRP (high-sensitivity), ESR, complement C3/C4, serum immunoglobulin levels, comprehensive safety panels, and drug trough level monitoring for biologic and JAK inhibitor trials.

Omega Genetics

HLA Typing & Risk Variants

HLA-B27 for axial spondyloarthritis stratification; HLA-DRB1 shared epitope for RA prognosis; PTPN22, STAT4, and IRF5 variants informing autoimmune disease patient selection.

Omega Biorepository

Serum & Synovial Fluid Archive

Serial serum and synovial fluid (where applicable) biobanking at -80\u00b0C for retrospective biomarker analysis, ADA re-testing, and translational immunology research.

Omega Care

Remote PRO & Joint Counts

Home-based DAS28, HAQ-DI, and pain NRS capture via mobile platform; wearable activity monitoring for RA and PsA patients; telemedicine joint assessment coordination.

Omega Bio

ADA & NAb Assay Kits

Kit-based ELISA harmonization for anti-drug antibody (ADA) screening and confirmation; cell-based neutralizing antibody (NAb) assay standardization across multi-center biologic trials.

Animal Facility

Arthritis & Lupus Models

Collagen-induced arthritis (CIA) models, adjuvant-induced arthritis, and NZB/W F1 lupus models for preclinical evaluation of biologics, JAK inhibitors, and emerging cell therapies.

Drive Your Rheumatology Trial Forward

Partner with Omega CRO for integrated rheumatology expertise, specialized laboratory services, and proven operational excellence.

Talk to Our Experts